Kim RB - Search Results

1

Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.

Yang T, McBride BF, Leake BF, Kim RB, Roden DM. Yang T, et al. Among authors: kim rb. Br J Pharmacol. 2010 Nov;161(5):1023-33. doi: 10.1111/j.1476-5381.2010.00932.x. Br J Pharmacol. 2010. PMID: 20977453 Free PMC article.

2

Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators.

O'Shea D, Kim RB, Wilkinson GR. O'Shea D, et al. Among authors: kim rb. Br J Clin Pharmacol. 1997 Jan;43(1):99-103. doi: 10.1111/j.1365-2125.1997.tb00039.x. Br J Clin Pharmacol. 1997. PMID: 9056059 Free article.

3

Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren.

Takahashi H, Kim RB, Perry PR, Wilkinson GR. Takahashi H, et al. Among authors: kim rb. J Pharmacol Exp Ther. 1997 Apr;281(1):297-303. J Pharmacol Exp Ther. 1997. PMID: 9103510

4

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. Kim RB, et al. J Clin Invest. 1998 Jan 15;101(2):289-94. doi: 10.1172/JCI1269. J Clin Invest. 1998. PMID: 9435299 Free PMC article.

5

Modulation by dietary salt of verapamil disposition in humans.

Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, Eichelbaum M, Roden DM. Darbar D, et al. Among authors: kim rb. Circulation. 1998 Dec 15;98(24):2702-8. doi: 10.1161/01.cir.98.24.2702. Circulation. 1998. PMID: 9851956 Clinical Trial.

6

Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants.

Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB. Fromm MF, et al. Among authors: kim rb. Biochim Biophys Acta. 1999 Jan 8;1415(2):369-74. doi: 10.1016/s0005-2736(98)00233-8. Biochim Biophys Acta. 1999. PMID: 9889399 Free article.

7

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].

Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Fromm MF, et al. Among authors: kim rb. Circulation. 1999 Feb 2;99(4):552-7. doi: 10.1161/01.cir.99.4.552. Circulation. 1999. PMID: 9927403

8

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Kim RB, et al. Pharm Res. 1999 Mar;16(3):408-14. doi: 10.1023/a:1018877803319. Pharm Res. 1999. PMID: 10213372

9

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. Cvetkovic M, et al. Among authors: kim rb. Drug Metab Dispos. 1999 Aug;27(8):866-71. Drug Metab Dispos. 1999. PMID: 10421612

10

Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.

Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, Wilkinson GR. Kim RB, et al. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9. J Pharmacol Exp Ther. 1999. PMID: 10565843

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

419 results

Search Page

Filters